Статья
В обзоре изложены основные сведения о процессах репликативного клеточного и сосудистого старения. Особое внимание уделяется проблеме артериальной гипертензии (АГ) и инсулинорезистентности (ИР). Обсуждаются механизмы возникновения ИР и АГ, их роль в развитии основных возраст-ассоциированных изменений сосудов, трансформации старения сосудов в болезнь, вклад в продолжительность жизни. Рассматриваются возможные пути воздействия на данные процессы.
1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. WHO, World Heart Federation, World Stroke Organization. 2017; p. 155.
2. Gardner IP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111(17):2171-2177. doi:10.1161/01.cir.0000163550.70487.0b
3. Akasheva DU, Plokhova EV, Tkacheva ON, Strazhesko ID, Dudinskaya EN, Kruglikova AS et al. Agerelated left ventricular changes and their association with leukocyte telomere length in healthy people. PLoS ONE. 2015;10(8):e0135883. doi.org/10.1371/journal.pone.0135883
4. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91 (7):1981-1987. doi:10.1161/01.cir.91.7.1981
5. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. I Clin Endocrinol Metab. 2005;90(5):2823-2827. doi:10.1210/jc.2004-1686
6. Бойцов С. А., Стражеско И. Д., Акашева Д. У, Дудинская Е. Н., Кругликова А. С., Ткачева О. Н. Инсулинорезистентность: благо или зло? Механизмы развития и связь с возраст-ассоциированными изменениями сосудов. Кардиоваскулярная терапия и профилактика, 2013;12(4):91-97.
7. Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2017;956:511-540. doi:10.1007/5584_2016_90
8. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361 (9355):393-395. doi:10.1016/S0140-6736(03)12384-7
9. Iellamo F, Caminiti G, Sposato B, Vitale C, Massaro M, Rosano G et al. Effect of High-Intensity interval training versus moderate continuous training on 24-h blood pressure profile and insulin resistance in patients with chronic heart failure. Intern Emerg Med. 2014;9(5):547-552. doi:10.1007/s11739-013-0980-4
10. Стрельцова Л. И., Ткачева О. Н., Дудинская Е. Н., Акашева Д. У, Плохова Е. В., Стражеско И. Д. и др. Возрастные изменения вариабельности ритма сердца при различной инсулиночувствительности и длине теломеров. Кардиология. 2017;7(57):52-60. doi:10.18087/cardio.2017.7.10006
11. Wang X, Haring MF, Rathjen T, Lockhart SM, S0rensen D, Ussar S et al. Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene. 2017;36(35):4987-4996. doi:10.1038/onc.2017.107
12. Verhulst S, Dalgard C, Labat C, Kark JD, Kimura M, Christensen K et al. A short leucocyte telomere length is associated with development of insulin resistance. Diabetologia. 2016;59 (6):1258—1265. doi:10.1007/s00125-016-3915-6
13. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-352.
14. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10):1133—1138.
15. Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10(5):274-283.
16. Brouilette SW, Moore JS, McMahon AD. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369(9556):107-114.
17. Nzietchueng R, Elfarra M, Nloga J. Telomere length in vascular tissues from patients with atherosclerotic disease. J Nutr Health Aging. 2011;15(2):153-156.
18. Fitzpatrick AL, Kronmal, RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiology. 2007;165(1):14-21. https://doi.org/10.1093/aje/kwj346
19. O’Donnell CJ, Demissie S, Kimura M, Levy D, Gardner IP, White C et al. Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2008;28(6):1165-1171.
20. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23 (5):842-846.
21. Yeh JK, Wang CY. Telomeres and telomerase in cardiovascular diseases. Genes (Basel). 2016;7(9): E58. doi:10.3390/genes7090058
22. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006;5(4):325-330. doi:10.1111/j.1474-9726.2006.00224.x
23. Zhou M, Zhu L, Cui X, Feng L, Zhao X, He S et al. Influence of diet on leukocyte telomere length, markers of inflammation and oxidative stress in individuals with varied glucose tolerance: a Chinese population study. Nutr J. 2016;15:39. https://doi.org/10.1186/s12937-016-0157-x
24. Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017;7 (11):e017184. doi:10.1136/bmjopen-2017-017184
25. Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR. Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab. 2005; 90(12):6650-6656.
26. De Haes W, Frooninckx L, Van Assche R, Smolders A, Depuydt G, Billen J et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci USA. 2014;111(24): E2501-E2509. doi:10.1073/pnas.1321776111
27. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7 (17):2769-2773. https://doi.org/10.4161/cc7.17.6625
28. Bannister SE, Holden S, Jenkins-Jones CL, Morgan JP, Halcox G, Schernthaner J et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in
29. people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16 (11):1165-1173. https://doi.org/10.1111/dom.12354
30. Justice JN, Ferrucci L, NewmanAB, Aroda VR, Bahnson JL, Divers J et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience. 2018;40(5-6):419-436. doi:10.1007/s11357-018-0042-y
31. Xin F, Lining W, Yao L. Change of telomere length in angiotensin ii-induced human glomerular mesangial cell senescence and the protective role of losartan. Mol Med Rep. 2011;4(2):255-260. https://doi.org/10.3892/mmr.2011.436
32. Boccardi V, Barbieri M, Rizzo M, Marfella R, Esposito A, Marano L et al. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. FASEB J. 2013;27(9):3879-3885.
33. Strazhesko ID, Tkacheva ON, Akasheva DU, Dudinskaya EN, Plokhova EV, Pykhtina VS et al. Atorvastatin therapy modulates telomerase activity in patients free of atherosclerotic cardiovascular diseases. Front Pharmacol. 2016;7:347. doi:10.3389/fphar.2016.00347